Cyr61 Expression Pattern and Association with Clinico-pathological Factors in Patients with Cervical Cancer

Sebastian Mayer*, Boris Gabriel, Thalia Erbes, Sylvia Timme-Bronsert, Markus Jaeger, Gerta Ruecker, Franciska Kuf, Jiri Bouda, Alena Bartakova, Axel Zur Hausen, Elmar Stickeler, Gerald Gitsch, Marc Hirschfeld

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Web of Science)

Abstract

Background/Aim: The pro-angiogenic Cyr61 protein has been associated with tumorigenesis and cancer progression in different gynecological carcinomas. In this study, we evaluated the potential impact and clinical relevance of Cyr61 expression in patients with primary non-metastatic cervical cancer (CC). Patients and Methods: Cyr61 expression was assessed in tissue specimen of 48 patients with primary CC by immunohistochemical analysis. Expression levels were scored and correlated to clinico-pathological factors and outcome data. Results: High Cyr61 expression levels were present in 54.2% of CC tissues. Associations with histological grade (p=0.030), depth of tumor invasion (p=0.007) and GOG score (p=0.027) were observed. Patients who overexpressed Cyr61 displayed an increased death rate (30.8% vs. 18.2%) and a decreased 5-year-survival (76.9% vs. 86.4%). Conclusion: Our data indicate a potential functional impact of Cyr61 in development and the progression of CC. The definite tumor-relevant function (suppressive/promoting) of Cyr61 in CC and the prognostic relevance of Cyr61 overexpression has to be evaluated in larger cohorts.

Original languageEnglish
Pages (from-to)2451-2456
Number of pages6
JournalAnticancer Research
Volume37
Issue number5
DOIs
Publication statusPublished - May 2017

Keywords

  • Cyr61
  • cervical cancer
  • hTra2 beta
  • overall survival
  • histologic grade
  • IMMEDIATE-EARLY GENE
  • ENDOMETRIAL CANCER
  • GROWTH
  • PROGNOSIS
  • METAANALYSIS
  • METASTASIS
  • CARCINOMA
  • FAMILY
  • CELLS
  • IL-6

Cite this